RT Journal Article
SR Electronic
T1 Severity of Omicron (B.1.1.529) and Delta (B.1.1.617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.29.22277044
DO 10.1101/2022.06.29.22277044
A1 Hyams, Catherine
A1 Challen, Robert
A1 Marlow, Robin
A1 Nguyen, Jennifer
A1 Begier, Elizabeth
A1 Southern, Jo
A1 King, Jade
A1 Morley, Anna
A1 Kinney, Jane
A1 Clout, Madeleine
A1 Oliver, Jennifer
A1 Ellsbury, Gillian
A1 Maskell, Nick
A1 Jodar, Luis
A1 Gessner, Bradford
A1 McLaughlin, John
A1 Danon, Leon
A1 Finn, Adam
A1 The Avon CAP Research Group
YR 2022
UL http://medrxiv.org/content/early/2022/06/30/2022.06.29.22277044.abstract
AB Limited data exist assessing severity of disease in adults hospitalised with Omicron SARS-CoV-2 variant infections, and to what extent patient-factors, including vaccination and pre-existing disease, affect variant-dependent disease severity. This prospective cohort study of all adults (≥18 years of age) hospitalised at acute care hospitals in Bristol, UK assessed disease severity using 3 different measures: FiO2 >28%, World Health Organization (WHO) outcome score >5, and hospital length of stay (LOS) >3 days following admission for Omicron or Delta variant infection.Independent of other variables, including vaccination, Omicron variant infection was associated with a statistically lower severity compared to Delta; risk reductions were 58%, 67%, and 16% for FiO2, WHO score, and LOS, respectively. Younger age and vaccination with two or three doses were also independently associated with lower COVID-19 severity. Despite lower severity relative to Delta, Omicron infection still resulted in substantial patient and public health burden following admission.Competing Interest StatementCH is Principal Investigator of the Avon CAP study which is an investigator-led University of Bristol study funded by Pfizer and has previously received support from the NIHR in an Academic Clinical Fellowship. JO is a Co-Investigator on the Avon CAP Study. AF is a member of the Joint Committee on Vaccination and Immunization (JCVI) and chair of the World Health Organization European Technical Advisory Group of Experts on Immunization (ETAGE) committee. In addition to receiving funding from Pfizer as Chief Investigator of this study, he leads another project investigating transmission of respiratory bacteria in families jointly funded by Pfizer and the Gates Foundation. LD, RC are members of SPI-M-O subgroups of SAGE and are also partly funded through AvonCAP. LD is a Co-Investigator of the AvonCAP study and has also received funding from Pfizer, UKRI and UKHSA for unrelated projects. EB, JS, JN, GE, LJ, BG, and JM are employees of Pfizer, Inc and may hold stock or stock options. The other authors have no relevant conflicts of interest to declare.Clinical Protocols https://www.isrctn.com/ISRCTN17354061 Funding StatementThis study is a University of Bristol sponsored study which was funded through an investigator-led collaborative grant by Pfizer IncAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Health Research Authority Research Ethics Committee (East of England, Essex), REC 20/EE/0157, including data collection under Section 251 of the 2006 NHS Act authorised by the Confidentiality Advisory Group.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this study are sensitive and cannot be made publicly available without breaching patient confidentiality rules.